Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease.
Iron
Non-motor
Parkinson’s disease
Quantitative susceptibility mapping
R2*
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
30
08
2020
accepted:
23
03
2021
pubmed:
17
4
2021
medline:
15
12
2021
entrez:
16
4
2021
Statut:
ppublish
Résumé
Although iron dyshomeostasis is associated with Parkinson's disease (PD) pathogenesis, the relationship between iron deposition and non-motor involvement in PD is not fully understood. In this study, we investigated basal ganglia and extra-basal ganglia system iron contents and their correlation with non-motor symptoms in drug-naïve, early-stage PD patients. We enrolled 14 drug-naïve, early-stage PD patients and 12 age/sex-matched normal controls. All participants underwent brain magnetic resonance imaging to obtain the effective transverse relaxation rate (R2*) and quantitative susceptibility mapping (QSM). Deep brain structures, including the nucleus accumbens, caudate nucleus, putamen, globus pallidus, thalamus, hippocampus, and amygdala, were delineated using the FSL-FIRST; the substantia nigra, red nucleus, and dentate nucleus were segmented manually. Inter-group differences in R2* and QSM values, as well as their association with clinical parameters of PD, were investigated. Substantia nigra and putamen R2* values were significantly higher in PD patients than in normal controls, despite no significant difference in QSM values. Regarding the non-motor symptom scales, PD sleep scale score negatively correlated with R2* values in the red nucleus and right amygdala, Scales for Outcomes in Parkinson's disease-Autonomic scores were positively correlated with R2* values in the right amygdala and left hippocampus, and cardiovascular sub-score of Non-Motor Symptoms Scale for PD was positively associated with the QSM value in the left hippocampus. In this study, iron content in the extra-basal ganglia system was significantly correlated with non-motor symptoms, especially sleep problems and dysautonomia, even in early-stage PD.
Sections du résumé
BACKGROUND
BACKGROUND
Although iron dyshomeostasis is associated with Parkinson's disease (PD) pathogenesis, the relationship between iron deposition and non-motor involvement in PD is not fully understood. In this study, we investigated basal ganglia and extra-basal ganglia system iron contents and their correlation with non-motor symptoms in drug-naïve, early-stage PD patients.
METHODS
METHODS
We enrolled 14 drug-naïve, early-stage PD patients and 12 age/sex-matched normal controls. All participants underwent brain magnetic resonance imaging to obtain the effective transverse relaxation rate (R2*) and quantitative susceptibility mapping (QSM). Deep brain structures, including the nucleus accumbens, caudate nucleus, putamen, globus pallidus, thalamus, hippocampus, and amygdala, were delineated using the FSL-FIRST; the substantia nigra, red nucleus, and dentate nucleus were segmented manually. Inter-group differences in R2* and QSM values, as well as their association with clinical parameters of PD, were investigated.
RESULTS
RESULTS
Substantia nigra and putamen R2* values were significantly higher in PD patients than in normal controls, despite no significant difference in QSM values. Regarding the non-motor symptom scales, PD sleep scale score negatively correlated with R2* values in the red nucleus and right amygdala, Scales for Outcomes in Parkinson's disease-Autonomic scores were positively correlated with R2* values in the right amygdala and left hippocampus, and cardiovascular sub-score of Non-Motor Symptoms Scale for PD was positively associated with the QSM value in the left hippocampus.
CONCLUSION
CONCLUSIONS
In this study, iron content in the extra-basal ganglia system was significantly correlated with non-motor symptoms, especially sleep problems and dysautonomia, even in early-stage PD.
Identifiants
pubmed: 33860863
doi: 10.1007/s10072-021-05223-0
pii: 10.1007/s10072-021-05223-0
pmc: PMC8642382
doi:
Substances chimiques
Pharmaceutical Preparations
0
Iron
E1UOL152H7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5297-5304Informations de copyright
© 2021. The Author(s).
Références
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13(10):1045–1060. https://doi.org/10.1016/S1474-4422(14)70117-6
doi: 10.1016/S1474-4422(14)70117-6
pubmed: 25231526
pmcid: 5672917
Surendran S, Rajasankar S (2010) Parkinson’s disease: oxidative stress and therapeutic approaches. Neurol Sci 31(5):531–540. https://doi.org/10.1007/s10072-010-0245-1
doi: 10.1007/s10072-010-0245-1
pubmed: 20221655
Telling ND, Everett J, Collingwood JF, Dobson J, van der Laan G, Gallagher JJ, Wang J, Hitchcock AP (2017) Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer's disease. Cell Chem Biol 24(10):1205–1215.e1203. https://doi.org/10.1016/j.chembiol.2017.07.014
doi: 10.1016/j.chembiol.2017.07.014
pubmed: 28890316
Ong WY, Farooqui AA (2005) Iron, neuroinflammation, and Alzheimer’s disease. J Alzheimers Dis 8(2):183–200; discussion 209-115. https://doi.org/10.3233/jad-2005-8211
doi: 10.3233/jad-2005-8211
pubmed: 16308487
Wang J-Y, Zhuang Q-Q, Zhu L-B, Zhu H, Li T, Li R, Chen S-F, Huang C-P, Zhang X, Zhu J-H (2016) Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements. Sci Rep 6:36669. https://doi.org/10.1038/srep36669
doi: 10.1038/srep36669
pubmed: 27827408
pmcid: 5101491
Pietracupa S, Martin-Bastida A, Piccini P (2017) Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review. Neurol Sci 38(12):2095–2101. https://doi.org/10.1007/s10072-017-3099-y
doi: 10.1007/s10072-017-3099-y
pubmed: 28866787
Langkammer C, Pirpamer L, Seiler S, Deistung A, Schweser F, Franthal S, Homayoon N, Katschnig-Winter P, Koegl-Wallner M, Pendl T, Stoegerer EM, Wenzel K, Fazekas F, Ropele S, Reichenbach JR, Schmidt R, Schwingenschuh P (2016) Quantitative susceptibility mapping in Parkinson’s disease. PLoS One 11(9):e0162460. https://doi.org/10.1371/journal.pone.0162460
doi: 10.1371/journal.pone.0162460
pubmed: 27598250
pmcid: 5012676
Du G, Lewis MM, Sica C, He L, Connor JR, Kong L, Mailman RB, Huang X (2018) Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson’s patients. Mov Disord 33(9):1423–1431. https://doi.org/10.1002/mds.27318
doi: 10.1002/mds.27318
pubmed: 29756399
pmcid: 6185755
Uchida Y, Kan H, Sakurai K, Arai N, Kato D, Kawashima S, Ueki Y, Matsukawa N (2019) Voxel-based quantitative susceptibility mapping in Parkinson’s disease with mild cognitive impairment. Mov Disord 34(8):1164–1173. https://doi.org/10.1002/mds.27717
doi: 10.1002/mds.27717
pubmed: 31091347
Thomas GEC, Leyland LA, Schrag A-E, Lees AJ, Acosta-Cabronero J, Weil RS (2020) Brain iron deposition is linked with cognitive severity in Parkinson’s disease. J Neurol Neurosurg Psychiatry 91(4):418–425. https://doi.org/10.1136/jnnp-2019-322042
doi: 10.1136/jnnp-2019-322042
pubmed: 32079673
Shin C, Lee S, Lee JY, Rhim JH, Park SW (2018) Non-motor symptom burdens are not associated with iron accumulation in early Parkinson’s disease: a quantitative susceptibility mapping study. J Korean Med Sci 33(13):e96. https://doi.org/10.3346/jkms.2018.33.e96
doi: 10.3346/jkms.2018.33.e96
pubmed: 29573246
pmcid: 5865060
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424
doi: 10.1002/mds.26424
pubmed: 26474316
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442. https://doi.org/10.1212/wnl.17.5.427
doi: 10.1212/wnl.17.5.427
pubmed: 6067254
Fahn S ER (1987) UPDRS program members. In: Fahn S, Marsden CD, Goldstein M, CalneDB, editors Unified Parkinson’s disease rating scale. Recent developments in Parkinson’s disease vol. 2. p153–163, 293–304
Diederich NJ, Moore CG, Leurgans SE, Chmura TA, Goetz CG (2003) Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 60(4):529–533. https://doi.org/10.1001/archneur.60.4.529
doi: 10.1001/archneur.60.4.529
pubmed: 12707066
Yook SKZ (1997) A clinical study on the Korean version of Beck anxiety inventory: comparative study of patient and non-patient. Korean J Clin Psychol 16(1):185–197
Choi SH, Na DL, Kwon HM, Yoon SJ, Jeong JH, Ha CK (2000) The Korean version of the neuropsychiatric inventory: a scoring tool for neuropsychiatric disturbance in dementia patients. J Korean Med Sci 15(6):609–615. https://doi.org/10.3346/jkms.2000.15.6.609
doi: 10.3346/jkms.2000.15.6.609
pubmed: 11194184
pmcid: 3054697
Brown RG, Dittner A, Findley L, Wessely SC (2005) The Parkinson fatigue scale. Parkinsonism Relat Disord 11(1):49–55. https://doi.org/10.1016/j.parkreldis.2004.07.007
doi: 10.1016/j.parkreldis.2004.07.007
pubmed: 15619463
J S, Baik JYK, Park JH (2005) Parkinson’s disease sleep scale in Korea. J Korean Neurol Assoc 23(1):41–48
Frauscher B, Ehrmann L, Zamarian L, Auer F, Mitterling T, Gabelia D, Brandauer E, Delazer M, Poewe W, Hogl B (2012) Validation of the Innsbruck REM sleep behavior disorder inventory. Mov Disord 27(13):1673–1678. https://doi.org/10.1002/mds.25223
doi: 10.1002/mds.25223
pubmed: 23192924
Kim J-Y, Song I-U, Koh S-B, Ahn T-B, Kim SJ, Cheon S-M, Cho JW, Kim YJ, Ma H-I, Park M-Y, Baik JS, Lee PH, Chung SJ, Kim J-M, Kim H-J, Sung Y-H, Kwon DY, Lee J-H, Lee J-Y, Kim JS, Yun JY, Kim HJ, Hong JY, Kim M-J, Youn J, Kim JS, Oh ES, Yang H-J, Yoon WT, You S, Kwon K-Y, Park H-E, Lee S-Y, Kim Y, Kim H-T, Kim J-S (2017) Validation of the Korean version of the scale for outcomes in Parkinson’s disease-autonomic. JMD 10(1):29–34. https://doi.org/10.14802/jmd.16057
doi: 10.14802/jmd.16057
pubmed: 28122431
pmcid: 5288668
Koh SB, Kim JW, Ma HI, Ahn TB, Cho JW, Lee PH, Chung SJ, Kim JS, Kwon DY, Baik JS (2012) Validation of the Korean-version of the nonmotor symptoms scale for Parkinson’s disease. JCN 8(4):276–283. https://doi.org/10.3988/jcn.2012.8.4.276
doi: 10.3988/jcn.2012.8.4.276
LE Lim SY, Jeong SW, Kim HC, Jeong CH, Jeon TY et al (2011) The validation study of Beck depression scale 2 in Korean version. Anxiety Mood 7:43–53
Kim JI, Sunwoo MK, Sohn YH, Lee PH, Hong JY (2016) The MMSE and MoCA for screening cognitive impairment in less educated patients with Parkinson’s disease. JMD 9(3):152–159. https://doi.org/10.14802/jmd.16020
doi: 10.14802/jmd.16020
pubmed: 27667187
pmcid: 5035941
Gudbjartsson H, Patz S (1995) The Rician distribution of noisy MRI data. Magn Reson Med 34(6):910–914. https://doi.org/10.1002/mrm.1910340618
doi: 10.1002/mrm.1910340618
pubmed: 8598820
pmcid: 2254141
Gho SM, Liu C, Li W, Jang U, Kim EY, Hwang D, Kim DH (2014) Susceptibility map-weighted imaging (SMWI) for neuroimaging. Magn Reson Med 72(2):337–346. https://doi.org/10.1002/mrm.24920
doi: 10.1002/mrm.24920
pubmed: 24006248
Nioche C, Cabanis EA, Habas C (2009) Functional connectivity of the human red nucleus in the brain resting state at 3T. AJNR 30(2):396–403. https://doi.org/10.3174/ajnr.A1375
doi: 10.3174/ajnr.A1375
pubmed: 19022864
pmcid: 7051406
Colpan ME, Slavin KV (2010) Subthalamic and red nucleus volumes in patients with Parkinson’s disease: Do they change with disease progression? Parkinsonism Relat Disord 16(6):398–403. https://doi.org/10.1016/j.parkreldis.2010.03.008
doi: 10.1016/j.parkreldis.2010.03.008
pubmed: 20452266
Enatsu R, Gonzalez-Martinez J, Bulacio J, Kubota Y, Mosher J, Burgess RC, Najm I, Nair DR (2015) Connections of the limbic network: a corticocortical evoked potentials study. Cortex 62:20–33. https://doi.org/10.1016/j.cortex.2014.06.018
doi: 10.1016/j.cortex.2014.06.018
pubmed: 25131616
Jhe N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, Liu C, Chen K, Yan F (2015) Region-specific disturbed iron distribution in early idiopathic Parkinson’s disease measured by quantitative susceptibility mapping. Hum Brain Mapp 36(11):4407–4420. https://doi.org/10.1002/hbm.22928
doi: 10.1002/hbm.22928
Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, Mailman RB, Huang X (2016) Quantitative susceptibility mapping of the midbrain in Parkinson’s disease. Mov Disord 31(3):317–324. https://doi.org/10.1002/mds.26417
doi: 10.1002/mds.26417
pubmed: 26362242
Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T (2019) Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease. Mov Disord 34(7):1006–1013. https://doi.org/10.1002/mds.27730
doi: 10.1002/mds.27730
pubmed: 31180615
pmcid: 6642003
Aquino D, Contarino V, Albanese A, Minati L, Farina L, Grisoli M, Elia A, Bruzzone MG, Chiapparini L (2014) Substantia nigra in Parkinson’s disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 35(5):753–758. https://doi.org/10.1007/s10072-013-1595-2
doi: 10.1007/s10072-013-1595-2
pubmed: 24337946
Liu Z, Shen H-C, Lian T-H, Mao L, Tang S-X, Sun L, Huang X-Y, Guo P, Cao C-J, Yu S-Y, Zuo L-J, Wang X-M, Chen S-D, Chan P, Zhang W (2017) Iron deposition in substantia nigra: abnormal iron metabolism, neuroinflammatory mechanism and clinical relevance. Sci Rep 7(1):14973–14973. https://doi.org/10.1038/s41598-017-14721-1
doi: 10.1038/s41598-017-14721-1
pubmed: 29097764
pmcid: 5668412
Li X, Xing Y, Schwarz ST, Auer DP (2017) Limbic grey matter changes in early Parkinson’s disease. Hum Brain Mapp 38(7):3566–3578. https://doi.org/10.1002/hbm.23610
doi: 10.1002/hbm.23610
pubmed: 28464508
pmcid: 6866728
Kalaitzakis ME, Gentleman SM, Pearce RK (2013) Disturbed sleep in Parkinson’s disease: anatomical and pathological correlates. Neuropathol Appl Neurobiol 39(6):644–653. https://doi.org/10.1111/nan.12024
doi: 10.1111/nan.12024
pubmed: 23363035
Yoo SW, Yun E, Bang M, Yoon U, Yoo JY, Lee KS, Shin NY, Kim JS (2020) Blood pressure lability is associated with subcortical atrophy in early Parkinson’s disease. J Hypertens 38(10):2043–2049. https://doi.org/10.1097/hjh.0000000000002505
doi: 10.1097/hjh.0000000000002505
pubmed: 32890281
Wang Y, Liu T (2015) Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker. Magn Reson Med 73(1):82–101. https://doi.org/10.1002/mrm.25358
doi: 10.1002/mrm.25358
pubmed: 25044035
Rua C, Clarke WT, Driver ID, Mougin O, Morgan AT, Clare S, Francis S, Muir KW, Wise RG, Carpenter TA, Williams GB, Rowe JB, Bowtell R, Rodgers CT (2020) Multi-centre, multi-vendor reproducibility of 7T QSM and R(2)* in the human brain: Results from the UK7T study. Neuroimage 223:117358. https://doi.org/10.1016/j.neuroimage.2020.117358
doi: 10.1016/j.neuroimage.2020.117358
pubmed: 32916289
Lotfipour AK, Wharton S, Schwarz ST, Gontu V, Schäfer A, Peters AM, Bowtell RW, Auer DP, Gowland PA, Bajaj NP (2012) High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson’s disease. J Magn Reson Imaging 35(1):48–55. https://doi.org/10.1002/jmri.22752
doi: 10.1002/jmri.22752
pubmed: 21987471